Nanjing, China – September 26, 2020 – MICRO-TECH today held a groundbreaking ceremony for its new headquarters and manufacturing facility in the Jiangbei New Area Biopharmaceutical Valley, marking a major step in scaling its manufacturing and innovation capabilities.
The new development follows the company’s successful listing on China’s STAR Market in 2019 and represents a key investment in supporting its next phase of high-growth expansion.
The new facility is designed to enhance MICRO-TECH’s integrated capabilities across manufacturing, R&D, and operations, positioning the company to better serve growing global demand for minimally invasive medical technologies.
Strategically located in Nanjing’s Jiangbei New Area, a rapidly developing hub for life sciences and biopharmaceutical innovation, the new site will support the company’s long-term ambition to strengthen both domestic and international market presence.
The groundbreaking ceremony was attended by MICRO-TECH’s senior leadership, key shareholders, construction partners, and representatives from the healthcare and industrial ecosystem.
Distinguished attendees included Mr Long Xiaohui, Chairman of MICRO-TECH; Mr Leng Derong, President; Mr Chris Li Changqing, Executive President, as well as representatives from key partners including Beijing Urban Construction Investment & Development Co., Ltd., Nantong No.4 Construction Group, and other stakeholders involved in the project.
Speaking at the ceremony, Long described the project as a defining milestone: “The groundbreaking of this new facility marks the beginning of a new chapter for MICRO-TECH. It is not just a building, but the foundation for our next stage of growth as a public company. From here, we will continue to pursue innovation, strengthen our capabilities, and build a company that delivers long-term value to society.”
He emphasized that while the physical infrastructure is critical, the company’s long-term success will depend equally on strengthening its strategy, organizational capabilities, and talent base.
Founded in 2000, MICRO-TECH has grown from a small startup into a leading player in minimally invasive medical technology, driven by continuous innovation and a strong focus on clinical needs.
Over the past two decades, the company has expanded from a single-product focus to multiple technology platforms, built advanced manufacturing and operational capabilities, and developed a growing international presence alongside its Chinese business.
The company’s growth has been underpinned by its guiding principles of innovation with integrity, craftsmanship, and customer-centricity, as well as its commitment to improving clinical outcomes, reducing patient burden, and lowering healthcare costs.
The new headquarters and manufacturing campus is expected to play a critical role in enabling MICRO-TECH to accelerate product innovation and development, scale manufacturing capacity with enhanced quality control, strengthen supply chain resilience, support global expansion and market access.
The project reflects MICRO-TECH’s confidence in the long-term growth of the medical device sector, which is entering a period of sustained expansion driven by ageing populations, rising healthcare demand, and increased adoption of minimally invasive procedures worldwide.
With construction now underway, MICRO-TECH aims to deliver a high-standard, future-ready facility that reflects its ambitions as a globally competitive medtech company.
As the company enters its third decade, the new development signals not just physical expansion, but a renewed commitment to innovation, operational excellence, and building a world-class organization for the future of healthcare.
